Experience with canakinumab in a patient with gout and IgA nephropathy
https://doi.org/10.14412/1996-7012-2019-3-71-75
Abstract
The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and high-dose glucocorticoids) and a history of failed urate-lowering therapy. It demonstrates the possibility of safely using subcutaneous canakinumab 150 mg that is superior to therapy with high-dose prednisone (40-80 mg/day) and NSAIDs. Canakinumab has also reduced the risk of exacerbations of arthritis when choosing urate-lowering therapy.
Keywords
About the Authors
E. V. Ilyinykh
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Ekaterina Valerievna Ilyinykh.
34A, Kashirskoe Shosse, Moscow 115522.
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
2. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am JMed. 2011 Feb;124(2):155-63. doi: 10.1016/j.amjmed.2010.09.012.
3. Neogi T. Clinical practice. Gout. N Engl J Med. 2011 Feb 3;364(5):443-52. doi: 10.1056/NEJMcp1001124.
4. Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs. 2008;68(4):407-15.
5. Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol. 2007 Jul;34(7):1566-8. Epub 2007 Jun 15.
6. Chikina MN. Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(6):760-6. (In Russ.). doi: 10.14412/1995-4484-2018-760-766
7. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 Jul; 70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3.
8. Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1 в blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(2): 16-22. (In Russ.). doi: 1996-7012-2015-2-16-22
9. Akahoshi T, Murakami Y, Kitasato H. Recent advances in crystal-induced acute inflammation. Curr Opin Rheumatol. 2007 Mar;19(2):146-50.
10. Martinon F, P?trilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9;440(7081):237-41. Epub 2006 Jan 11.
11. So A, Meulemeester De, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010 Oct;62(10): 3064-76. doi: 10.1002/art.27600.
12. Schlesinger N, Alten R, Bardin T, et al. Canakinumab in frequently flaring gouty arthritis patients, contraindicated, intolerant or unresponsive to non-steroidal anti-inflammatory drugs and/or colchicine: safety and efficacy results from long term follow-up. Arthritis Rheum. 2014;66:S66—S67.
13. Bardin T, So A, Alten R, et al. Efficacy and safety of canakinumab vs triamcinolone acetonide in patients with gouty arthritis unable to use nonsteroidal anti-inflammatory drugs and colchicine, and on stable urate lowering therapy (ULT) or unable to use ULT. Arthritis Rheum. 2012;64:S811—S812.
14. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011 Mar 25;13(2):R53. doi: 10.1186/ar3297
15. Eliseev MS, Zhelyabina OV, Barskova VG, Nasonov EL. Experience of administration of canakinumab, an interleukin 1в inhibitor, in a patient with chronic tophacaceous gout. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):99—101. (In Russ.). doi: 10.14412/1995-4484-2014-99-101
16. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012 Nov;71(11):1839-48. doi: 10.1136/annrheumdis-2011-200908. Epub 2012 May 14.
17. Lowry F. FDA panel says no to canakinumab for gout attacks. 2011. www.medscape.com/viewarticle/745076
18. Vianna HR, Soares CM, Tavares MS, et al. Inflammation in chronic kidney disease: the role of cytokines. J Bras Nefrol. 2011 Jul-Sep;33(3):351-64.
19. Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010 Oct;21(10):1732-44. doi: 10.1681/ASN.2010020143. Epub 2010 Aug 5.
20. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979 Jul;67(1):74-82.
21. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015 Apr 1;17:90. doi: 10.1186/s13075-015-0610-9.
22. Singh JA, Yu S. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure. Ann Rheum Dis. 2017 Jan;76(1):133-139. doi: 10.1136/annrheumdis-2015-209046. Epub 2016 Jun 13.
23. Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014 May;41(5):955-62. doi: 10.3899/jrheum.131159. Epub 2014 Apr 1.
24. Bakan A, Oral A, Elcioglu OC, et al. Hyperuricemia is associated with progression of IgA nephropathy. Int Urol Nephrol. 2015 Apr;47(4):673-8.
25. Caliskan Y, Ozluk Y, Celik D, et al. The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy. Kidney Blood Press Res. 2016;41(2):148-57. doi: 10.1159/000443415. Epub 2016 Feb 26.
26. Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153-60. doi: 10.1159/000331453. Epub 2011 Nov 23.
27. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk fac-tors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012 Apr;27(4):1479-85. doi: 10.1093/ndt/gfr527. Epub 2011 Sep 29.
28. Nasri H, Baradaran A. Aggravation of immunoglobulin a nephropathy by hyperuricemia: a mini-review on current findings and new concepts. Iran J Kidney Dis. 2014 Sep;8(5):359-62.
Review
For citations:
Ilyinykh EV, Eliseev MS. Experience with canakinumab in a patient with gout and IgA nephropathy. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(3):71-75. (In Russ.) https://doi.org/10.14412/1996-7012-2019-3-71-75
Views:
1021
Email this article 